Literature DB >> 12447954

Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.

L P Koh1, A Kurup, Y T Goh, S M C Fook-Chong, P H C Tan.   

Abstract

Over the past decade, invasive fungal infections have become an increasingly important problem in patients undergoing hematopoietic stem cell transplantation (HSCT). The optimal approach for prophylactic antifungal therapy has yet to be determined. To resolve this issue, we performed a prospective randomized study to compare the efficacy of fluconazole (FL) versus low-dose amphotericin B (AmB) in preventing fungal infections during the first 100 days after HSCT. Patients undergoing allogenic or autologous HSCT were randomized to receive fluconazole 200 mg/day PO or amphotericin B 0.2 mg/kg/day IV beginning 1 day prior to commencement of conditioning regimen and continuing until engraftment, drug-associated toxicity was suspected, or systemic fungal infection was suspected or proven. High-dose amphotericin B (0.5-1.0 mg/kg/day) was started for patients with suspected or proven fungal infections. From January 1993 to December 1998, a total of 186 patients were enrolled into the trial, with 100 receiving FL and 86 receiving AmB. Eighty (43%) patients were removed from prophylaxis for persistent fever despite broad-spectrum antibacterial therapy or suspected fungal infections (FL 46 vs. AmB 34, P > 0.05). The incidence of proven fungal infections (FL 12% vs. AmB 12.8%), suspected fungal infections (FL 4% vs. AmB 2.3%), superficial fungal infections (FL 1% vs. AmB 4.6%) did not show any significant difference. The survival at 100 days post transplant was similar between the 2 groups (FL 78% vs. AmB 70%, P = 0.254). Death attributable to fungal infections was similar in both groups (6% vs. 7%, P > 0.05). We conclude that fluconazole is as effective as low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic cell transplantation. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12447954     DOI: 10.1002/ajh.10234

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  14 in total

Review 1.  Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.

Authors:  Anna B Halpern; Gary H Lyman; Thomas J Walsh; Dimitrios P Kontoyiannis; Roland B Walter
Journal:  Blood       Date:  2015-10-26       Impact factor: 22.113

2.  Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.

Authors:  Maria Siopi; Nikolaos Siafakas; Sophia Vourli; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

Review 3.  Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients.

Authors:  Helle Krogh Johansen; Peter C Gøtzsche
Journal:  Cochrane Database Syst Rev       Date:  2014-09-04

4.  Clinical evaluation of ERCP and naobiliary drainage for biliary fungal infection--a report of five cases of severe combined bacterial and fungal infection of biliary tract.

Authors:  Qiu Zhao; Jiazhi Liao; Hua Qin; Jialong Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

5.  Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Cho-Hao Lee; Chin Lin; Ching-Liang Ho; Jung-Chung Lin
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

Review 6.  Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.

Authors:  Eric J Bow; David J Vanness; Monica Slavin; Catherine Cordonnier; Oliver A Cornely; David I Marks; Antonio Pagliuca; Carlos Solano; Lael Cragin; Alissa J Shaul; Sonja Sorensen; Richard Chambers; Michal Kantecki; David Weinstein; Haran Schlamm
Journal:  BMC Infect Dis       Date:  2015-03-17       Impact factor: 3.090

7.  The prevalence of antifungal agents administration in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective study.

Authors:  Mona Kargar; Alireza Ahmadvand; Milad Ahmadvand; Molouk Hadjibabaie; Kheirollah Gholami; Seyed Hamid Khoee; Mohammad Reza Javadi; Ardeshir Ghavamzadeh
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2013

Review 8.  Antifungal Therapy in Hematopoietic Stem Cell Transplant Recipients.

Authors:  Alessandro Busca; Livio Pagano
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-09-01       Impact factor: 2.576

9.  Comparative effectiveness of antifungal agents in patients with hematopoietic stem cell transplantation: a systematic review and network meta-analysis.

Authors:  Hui-Chen Su; Yi-Ming Hua; I Jung Feng; Hung-Chang Wu
Journal:  Infect Drug Resist       Date:  2019-05-15       Impact factor: 4.003

Review 10.  Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials.

Authors:  M C Ethier; M Science; J Beyene; M Briel; T Lehrnbecher; L Sung
Journal:  Br J Cancer       Date:  2012-05-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.